# Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

> **NCT06013618** · PHASE2 · RECRUITING · sponsor: **Sun Yat-Sen University Cancer Center** · enrollment: 120 (estimated)

## Conditions studied

- Neuroblastoma

## Interventions

- **DRUG:** Naxitamab monotherapy
- **DRUG:** GM-CSF
- **DRUG:** Irinotecan
- **DRUG:** Temozolomide
- **DRUG:** Naxitamab in combination therapy
- **DRUG:** GM-CSF with combination regimen
- **DRUG:** Sintilimab

## Key facts

- **NCT ID:** NCT06013618
- **Lead sponsor:** Sun Yat-Sen University Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-19
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-06-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06013618

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06013618, "Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06013618. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*